Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $11.49B | +2.6% | $2.68B | $1.31 | +9.2% | 70.2% | 29.3% |
| Q4 2025 Dec 2025 | $12.50B | — | $1.09B | $0.53 | — | 67.2% | 22.5% |
| Q3 2025 Sep 2025 | $12.22B | — | $2.20B | $1.08 | — | 71.9% | 29.8% |
| Q2 2025 Jun 2025 | $12.27B | — | $1.31B | $0.64 | — | 72.5% | 30.8% |
| Q1 2025 Mar 2025 | $11.20B | — | $2.46B | $1.20 | — | 72.9% | 31.2% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Will the combination of new global price caps and looming patent cliffs permanently derail Bristol Myers Squibb's long-term growth story?